ArticleDiseases (Basel, Switzerland)2025
In Vitro Activity of Silver-Bound Titanium Dioxide (Tiab) Against Multidrug-Resistant Bacteria from Dermatological Infections.
Article in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-term effectiveness of titanium dioxide-silver composite coating in reducing healthcare-associated infections in chronic respiratory care wards: a controlled trial.BMC infectious diseases · 2026Article
- Microbiological Spectrum and Antimicrobial Resistance Patterns in Hand Surgery Infections: A Monocentric Retrospective Study.Pathogens (Basel, Switzerland) · 2026Observational
- In Vitro Activity of Silver-Bound Titanium Dioxide (TiAB) Against Multidrug-Resistant Vaginal Pathogens.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the in vitro antimicrobial activity of TiAB, a compound based on silver-bound titanium dioxide, against clinical isolates from dermatological infections.
methodsWe tested 155 strains clinically isolated from ulcers and skin infections, including MRSA, ESBL-producing
resultsTiAB exhibited strong bactericidal activity against Gram-negative bacteria, including ESBL-positive
conclusionsTiAB exhibited in vitro bactericidal activity with median MIC values ranging from 1% to 2% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.